Very professional, the staff was very nice and helpful in my situation. Glad I made the appointment here because they wasted no time in getting me the information I needed.
You couldn't ask for a better staff. They are courteous, helpful and really know their stuff.
Thank you Doctor Ahlering for giving me the potential for a future. Your leadership and skill is reflected throughout your wonderful caring team who navigated me through this phase of my journey and treated me as if I was one of your own family.
My recovery exceeded every expectation that I had. After the surgery I was basically pain free and only took 1 Tylenol tablet! I was able to walk at length couple of days after the surgery. I did not even feel weak as one expects after the surgery.
Very professional staff, I like the rapport that they build with their patients. I took my son in for a procedure and the medical assistants took me under their wings and explained every step of the procedure in detail. I couldn't had chosen a better facility.
I have been treated by Dr. Louie and have nothing but good things to say about it. He is friendly, knowledgeable and will answer all the questions posed. In other words he has good bedside manner.
Xiaolin Zi obtained his M.Sc. degree in Biostatistics from McGill University, Canada and Ph.D. degree in Epidemiology from Shanghai Medical University, China. In 1996, Dr. Zi came to the United States to pursue post-doctoral training at Case Western University, Cleveland, OH and studied receptor tyrosine kinases-mediated cell cycle regulation and apoptotic pathways by novel cancer preventive agents. In 2002, Dr. Zi joined the Department of Urology at University of California, Irvine (UCI) as an Assistant Professional Researcher to start his own lab. In 2008, he was promoted to a Tenured Associate Professor of Urology at UCI. Dr. Zi holds a secondary appointment in the Department of Pharmacology, and is the Director of Urological Research at UCI. Dr. Zi has served on various national and international grant review panels and on Editorial Boards of various scientific journals, including PLOS ONE, Bladder, and American Journal of Clinical and Experimental Urology. He has served as a reviewer for more than 50 scientific journals. His research has been funded by NIH, DOD and AICR funding agencies. The two major areas of his research in urological cancers are naturally-occurring bioactive compounds and Wnt signaling with an emphasis on epithelial to mesenchymal transition. He combined his knowledge in population science with laboratory skills in basic science and identified flavokawain A as a novel apoptosis inducer from the KAVA plant for cancer prevention. His NIH funded research discovered that lycopene supplementation can enhance anti-tumor efficacy of docetaxel in a prostate cancer mouse xenograft model. In collaboration with Dr. Michael B. Lilly, Professor, Medical oncologist, and Associate Director for Translational Research at MUSC's Hollings Cancer Center, the study on lycopene and docetaxel combination in treatment of castration-resistant prostate cancer is also now in a NCI funded Phase I clinical trial. He also reported that secreted Wnt antagonists Frzb and WIF1 act as tumor suppressors to inhibit epithelial to mesenchymal transition and tumor metastasis. He is now developing Wnt antagonists and Bevacizumab, a humanized anti-VEGF antibody, combination therapy for treatment of castration-resistant prostate cancer. His lab has established several lines of patient-derived xenograft prostate cancer models and human prostate stromal cell lines.
Disclaimer : All content posted on this website is commentary or opinion. This website does not give or attempt to give medical advice and your personal information is not stored. THIS WEBSITE IS NOT DESIGNED TO – AND DOES NOT – PROVIDE MEDICAL ADVICE.